Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Pfizer Inc sold 700 million shares in Haleon PLC, as planned, more than halving its remaining stake, placing agent JP ...
Pfizer Inc is selling 700 million shares in Haleon PLC, more than halving its remaining stake, according to a stateme ...
Pfizer Inc on Tuesday said it is targetting another USD500 million of cost savings after projecting sales and earning ...
Hundreds of people in the UK with a rare and incurable type of blood cancer are set to benefit from a new drug that h ...
Pfizer Inc on Tuesday raised its annual guidance, as it reported strong growth in quarterly sales. The New York City ...
ridge, Surrey-based consumer healthcare firm spun-out of GSK PLC in 2022 - Announces it has completed an off-market pu ...
Pfizer Inc sold a 7.6% stake in consumer health products firm Haleon PLC for GBP2.7 billion, the investment banks run ...
Pfizer Inc on Monday said it plans to sell a 5.9% stake in consumer products firm, Haleon PLC, in a deal that could r ...
A multimillion-pound legal battle between rival developers of Covid-19 jabs over vaccine technology patents is set to ...
Pfizer Inc on Monday reported positive results from patients involved in phase 2 studies of ponsegromab and Braftovi ...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.35 | -1.31578947368 | 26.6 | 26.6 | 26.25 | 33401 | 26.3331036 | DE |
| 4 | -0.1 | -0.379506641366 | 26.35 | 27.85 | 26.25 | 35740 | 26.74280962 | DE |
| 12 | -2.15 | -7.57042253521 | 28.4 | 28.55 | 24.65 | 468567 | 27.432735 | DE |
| 26 | -3.4 | -11.4671163575 | 29.65 | 30.95 | 24.65 | 300639 | 28.20275606 | DE |
| 52 | -1.85 | -6.58362989324 | 28.1 | 30.95 | 24.65 | 309369 | 27.81297128 | DE |
| 156 | -26.645 | -50.373381227 | 52.895 | 54.995 | 24.65 | 291032 | 36.14067703 | DE |
| 260 | -14.25 | -35.1851851852 | 40.5 | 60.675 | 24.65 | 194624 | 36.87797803 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
